Table 2. Adverse events during the intervention period, control period and follow-up period in absolute numbers and percentages.

	Intervention period (n = 24)	Control period (n = 11)	Follow-up period (n = 19)
Serious adverse event, n(%)	0	0	1(5.3)
≥1 adverse event, n(%)	12(57.1)	9(81.2)	7(36.8)
Anterior uveitis, n(%)	0	1(9.1)*	1(5.3)*
Headache, n(%)	1(4.8)*	0	0
Common cold, n(%)	4(19.0)	2(18.2)	3(15.8)
Other infectious diseases, n(%)	2(9.5)	2(18.2)	1(5.3)
Other adverse events, n(%)	5(23.8)	4(36.4)**	2(10.5)

*Adverse events with moderate severity

**One out of four had a moderate severity